Uncertain compassion in using a drug before the risks and benefits are known

Archives of Ophthalmology

Volumn 124, Issue 7, 2006, Pages 1032-1034

  Narayanan, Raja ^a,b   Kuppermann, Baruch D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b L V PRASAD EYE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BEVACIZUMAB; NATALIZUMAB; RANIBIZUMAB; ROFECOXIB; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE;

CARDIOVASCULAR DISEASE; CATARACT; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG SCREENING; DRUG USE; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; OFF LABEL DRUG USE; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; RETINA DISEASE; RISK BENEFIT ANALYSIS; SHORT SURVEY; STROKE;

CLINICAL TRIALS, PHASE III; DRUG THERAPY; EMPATHY; EYE DISEASES; HUMANS; RISK ASSESSMENT;

EID: 33745827412     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.7.1032     Document Type: Short Survey

References (10)

1. Canner PL. Aspirin in coronary heart disease: comparison of six clinical trials. Isr J Med Sci. 1983;19:413-423.
2. Couzin J. Drug safety: FDA panel urges caution on many anti-inflammatory drugs. Science. 2005;307:1183-1185.
3. Gellene D. Biogen: second patient has rare ailment. Los Angeles Times. March 4, 2005:C2.
4. 4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:68-72.
5. Smiddy WE, Glaser BM, Thompson JT, et al. Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes: preliminary anatomic results of a multicenter prospective randomized study. Retina. 1993;13:296-301.
6. Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, Pena RA. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes: a prospective randomized study. Ophthalmology. 1992;99:1162-1172.
7. Thompson JT, Smiddy WE, Williams GA, et al. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery. Ophthalmology. 1998;105:700-706.
8. Hawkins BS, Bressler NM, Miskala PH, et al; Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology. 2004;111:1967-1980.
9. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol. 1997;115:865-872.
10. Rosenfeld PJ, Moshfeghi AA, Puliafito CA; Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-339.